Hims & Hers
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Through the acquisition, the company will expand its operations in the UK and launch operations in Germany, France and Ireland.
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
The aim is to offer a broader range of personalized treatment options to patients.
Two U.S. senators and the Partnership for Safe Medicines sent letters to the FDA, raising concerns that the ad fails to disclose safety and side effect information required in pharmaceutical advertising.